Efficacy and safety of iguratimod in the treatment of rheumatic and autoimmune diseases: a meta-analysis and systematic review of 84 randomized controlled trials.

Front Pharmacol · 2023 · PMC10740187 · PMID 38143490

Europe PMC DOI

hedged sentence

0.2100

closest p · 4.2× alpha

0.2100

boldest claim

The sentences

did not reach statistical significancep = 0.21not close (p > 0.1)

The findings of the meta-analysis indicate that the IGU + MTX group had a lower ACR70 than the control group (RR 1.84 [1.27, 2.67], p = 0.001; random effect model), while the difference between the IGU only group and the control group did not reach statistical significance (RR 1.51 [0.79, 2.86], p = 0.21; random effect model) ( Figure 6 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.